FUTURE PLANS

See "Business—Our Strategies" for details of our future plans.

USE OF [REDACTED]

Assuming an [**REDACTED**] of HK$[**REDACTED**], being the mid-point of the indicative [**REDACTED**] range, and after deducting estimated [**REDACTED**] fees and the estimated [**REDACTED**] expenses in connection with the [**REDACTED**] and [**REDACTED**], the [**REDACTED**] is not exercised, we estimate that the aggregate [**REDACTED**] from the [**REDACTED**] will be approximately HK$[**REDACTED**].

In line with our strategies, we intend to use the net [**REDACTED**] we will receive from the [**REDACTED**] for the following purposes, subject to changes in light of our evolving business needs and changing market conditions:

(a) Approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund our research and development activities and commercialization of our Core Product, among which:

(i) approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund the continuous R&D of our Core Product, including application expansion of TH-S1 in retroperitoneal lesions, for which we commenced the registrational trial in November 2025 and plan to submit registration application to the NMPA in the fourth quarter in 2026; completion of clinical trials for our 5G remote-surgery module with a planned registration submission in the second half of 2028; alongside finalization of CT/MRI-ultra ultrasound multimodal image fusion capabilities targeted for staged approvals and rollouts in the second half of 2030; ongoing enhancement of product performance and functionality, localization of critical components, and advancement of intelligent control system research; and expansion and protection of our intellectual property through continued patent filings and portfolio development;

(ii) approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund CE certification with a formal application targeted in the first quarter of 2026, followed by phased overseas registrations in Saudi Arabia, Brazil, the United States, and other target markets; and

(iii) approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund the commercialization of our Core Product. We plan to continue to advance hospital advancement, targeting installations in a number of reputable hospitals in China by 2028. To achieve the aforementioned commercialization plans, we expect to (i) build a sales and marketing team; (ii) establish a clinical and after-sales service team; (iii) continuously build and expand our sales market network through establishing marketing centers in key cities in China; and (iv) set up training programs with hospitals on the implementation of our percutaneous puncture robots: and

(b) Approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund research and development activities and commercialization of our key products, among which:

(i) approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund the continuous R&D of TH-X MW, including application expansion in lung tumor treatment for which we plan to complete the registration in the third quarter of 2026, and further conduct real-world evidence clinical study to generate insights that will guide future product upgrades and iterations continuous research and development to enhance product performance and functionality; and ongoing patent filings and portfolio development; and

(ii) approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to accelerate the commercialization of our key products. To achieve the aforementioned commercialization plans, we expect to (i) build a sales and marketing team; (ii) establish a clinical and after-sales service team; (iii) continuously build and expand our sales market network through establishing marketing centers in key cities in China; and (iv) conduct advanced function verification and clinical feedback collection with hospitals with respect to our microwave ablation robots; and

(c) Approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund research and development activities of other product candidates and related patent filings and portfolio expansion, among which:

(i) approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund the research and development of cryoablation robot. We plan to complete research and verification of the cryoablation robot in the second half of 2027, and submit the registration application to the NMPA in the second half of 2027, which we expect to obtain a registration approval in the first half of 2028; and

(ii) approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund the research and development of organ preservation and assessment systems. We plan to continue the development of organ preservation and assessment devices based on normothermic continuous mechanical perfusion, with the first clinical trial for kidney preservation and assessment commencing in the first half of 2027. In addition, we plan to commence a registrational trial of our multi-organ perfusion system in the first half of 2028;

(d) Approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund the expansion of our manufacturing capacity and enhance our production capability, among which:

(i) approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund the expansion of the Zhuhai application training, R&D testing, and manufacturing site to 10,000 m^2;

(ii) approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund the acquisition of equipment such as specialized tooling and articulated arm coordinate measuring machines;

(iii) approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund the upgrading of the ERP system and implementing a Manufacturing Execution System (MES) and a Quality Management System (QMS) to enable end-to-end traceability, support zero-defect quality, improve assembly efficiency, and comply with medical device regulations, including those implemented by the NMPA, the FDA and MDR; and

(iv) approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund the expansion of our production team. We plan to recruit more than 30 production and quality management staff over the next five years;

(e) Approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund the establishment of our sales network, expansion of our sales team and commercial cooperation for our products other than our Core Product and TH-X MW. To achieve the plans, we expect to recruit qualified candidates to develop and foster our relationships with potential end users in China. In addition, we expect to set up and operate several training centers for organ perfusion robots in key cities such as Beijing, Shanghai, and Guangzhou; and

(f) Approximately HK$[**REDACTED**] (representing [**REDACTED**]% of [**REDACTED**]) to fund our working capital and other general corporate purposes.

If the [**REDACTED**] is set at the high point or the low point of the indicative [**REDACTED**] range (assuming the [**REDACTED**] is not exercised), the [**REDACTED**] will increase or decrease by approximately HK$[**REDACTED**]. We will apply the additional or reduced [**REDACTED**] to the above purposes on a pro-rata basis.

If the [**REDACTED**] is exercised in full, we will receive additional [**REDACTED**] of approximately HK$[**REDACTED**], assuming an [**REDACTED**] of HK$[**REDACTED**] per Share, being the mid-point of the indicative [**REDACTED**] range.

If the [**REDACTED**] are not immediately applied to the above purpose, we will only deposit those [**REDACTED**] into short-term interest-bearing accounts at licensed commercial banks and/or other authorized financial institutions (as defined under the Securities and Futures Ordinance or applicable laws and regulations in other jurisdictions).

We currently have no specific plans as to how the [**REDACTED**] from this [**REDACTED**] will be allocated beyond the uses specified above, and therefore management will retain discretion to allocate the remainder of the [**REDACTED**] of this [**REDACTED**] among these uses.

This expected use of the [**REDACTED**] from this [**REDACTED**] represents our intentions based upon our current plans and business conditions. As of the Latest Practicable Date, we could not predict with certainty all of the particular uses for the [**REDACTED**] to be received upon the completion of this [**REDACTED**] or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures and the extent of clinical development may vary significantly depending on numerous factors, including the progress of our drug development programs, the status of and results from pre-clinical studies and any ongoing clinical trials or clinical trials we may commence in the future, as well as any collaborations that we may enter into with third parties for our drug candidates and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the [**REDACTED**] from this [**REDACTED**] and may change the allocation of use of these [**REDACTED**] among the uses described above. An [**REDACTED**] will not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use the [**REDACTED**].

We will issue an appropriate announcement if there is any material change in the abovementioned [**REDACTED**].